CAS: 16269-66-2; 4-Chlorothieno[3,2-D]Pyrimidine

相似化合物

16234-14-3 319442-16-5 225382-62-7

上下游产品

CAS号16234-10-9 4-羟基噻吩并[3,2-d]嘧啶 | CAS号75-34-3 1,1-二氯乙烷标准溶液 | CAS号1336-21-6 氨水 | CAS号79-37-8 草酰氯 | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号22288-78-4 3-氨基-2-噻吩甲酸甲酯 | CAS号31169-27-4 7-溴-4-氯噻酚并[3,2-D]嘧啶 | CAS号31169-25-2 7-溴噻吩并[3,2-d]嘧啶... | CAS号108134-22-1 4-氯-6-甲基噻吩并[3,2-d]嘧啶 | CAS号272-68-4 噻吩并[3,2-D]嘧啶 | CAS号31169-27-4 7-溴-4-氯噻酚并[3,2-D]嘧啶 | CAS号875515-76-7 4-氯-噻吩并[3,2-d]嘧... | CAS号225382-62-7 4-氯-6-碘噻吩并[3,2-D]嘧啶 | CAS号225385-03-5 6-溴-4-氯噻吩[3,2-D]嘧啶 | CAS号596794-87-5 Ethyl 4-chlorot... | CAS号31492-65-6 4-氯噻吩并[3,2-d]嘧啶 | CAS号16229-26-8 4-Hydrazinothie... | CAS号21586-25-4 7-溴噻吩并[3,2-d]嘧啶

噻吩并[3,2-D]嘧啶,4-(甲硫基)-置于磺酰氯体系中,用 二氯甲烷,乙腈 用作溶剂,化学反应 0.5H,以99%的收率获得4-氯噻吩并[3,2-D]嘧啶
参考文献:用硫酰氯对嘧啶环系统上的甲基硫烷基进行有效的一步氯化
标题:用硫酰氯对嘧啶环系统上的甲基硫烷基进行有效的一步氯化
摘要:使用乙腈/二氯甲烷中的硫酰氯,可轻松实现嘧啶环系统上甲基硫烷基和芳基硫烷基的一步式转化为相应的氯基.
Doi:10.1016/j.Tetlet.2010.06.056

专利信息

专利号:US-11332462-B2
优先权日:2012-02-08
标 题 :Heteroaryl compounds and methods of use thereof
发明人：CAMPBELL JOHN EMMERSON; CAMPBELL UNA; HANANIA TALEEN G; SHAO LIMING
权利人:SUNOVION PHARMACEUTICALS INC; PGI DRUG DISCOVERY LLC
摘要:Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

专利号:US-8378104-B2
优先权日:2010-02-11
标 题 :7-aminofuropyridine derivatives
发明人：HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
权利人:OSI PHARMACEUTICALS LLC; HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
摘要:Compounds of Formula 1, as shown below and defined herein: n n n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.